Should I buy or sell ABIVAX Société Anonyme stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ABIVAX Société Anonyme in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABVX shares. View ABVX analyst ratings or view top-rated stocks .

What is ABIVAX Société Anonyme's stock price target for 2024?

5 equities research analysts have issued 1 year target prices for ABIVAX Société Anonyme's shares. Their ABVX share price targets range from $16.00 to $50.00. On average, they predict the company's share price to reach $32.00 in the next year. This suggests a possible upside of 120.1% from the stock's current price. View analysts price targets for ABVX or view top-rated stocks among Wall Street analysts .

How have ABVX shares performed in 2024?

ABIVAX Société Anonyme's stock was trading at $10.70 at the start of the year. Since then, ABVX shares have increased by 35.9% and is now trading at $14.54. View the best growth stocks for 2024 here .

Are investors shorting ABIVAX Société Anonyme?

ABIVAX Société Anonyme saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 113,800 shares, a decline of 29.5% from the March 31st total of 161,500 shares. Based on an average daily volume of 74,700 shares, the short-interest ratio is presently 1.5 days. Approximately 0.2% of the company's shares are sold short. View ABIVAX Société Anonyme's Short Interest .

When did ABIVAX Société Anonyme IPO?

ABIVAX Société Anonyme (ABVX) raised $217 million in an IPO on Friday, October 20th 2023. The company issued 18,699,460 shares at a price of $11.60 per share.

When did ABIVAX Société Anonyme's lock-up period expire?

ABIVAX Société Anonyme's lock-up period expired on Wednesday, April 17th. ABIVAX Société Anonyme had issued 18,699,460 shares in its IPO on October 20th. The total size of the offering was $216,913,736 based on an initial share price of $11.60. Since the end of ABIVAX Société Anonyme's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Who are ABIVAX Société Anonyme's major shareholders?

ABIVAX Société Anonyme's stock is owned by a variety of retail and institutional investors. Top institutional investors include Rosalind Advisors Inc. (0.60%), Capstone Investment Advisors LLC (0.10%) and BNP Paribas Financial Markets (0.01%).

How do I buy shares of ABIVAX Société Anonyme?

Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ABVX

ABIVAX Société Anonyme (ABVX) Stock Price, News & Analysis

→ Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad)

Free ABVX Stock Alerts

$14.54

-0.38 (-2.55%)

(As of 05/3/2024 ET)

Compare

Today's Range: $14.32
▼
$15.10
50-Day Range: $13.06
▼
$15.89
52-Week Range: $7.99
▼
$17.02

Volume: 30,339 shs
Average Volume: 44,202 shs
Market Capitalization: $915.00 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $32.00

Get ABIVAX Société Anonyme alerts:

ABIVAX Société Anonyme MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 120.1% Upside
$32.00 Price Target
Short Interest: Healthy
0.19% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.61
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.98) to ($2.90) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.76 out of 5 stars

Medical Sector

403rd out of 904 stocks

Pharmaceutical Preparations Industry

182nd out of 423 stocks

3.4

Analyst's Opinion

Consensus Rating
ABIVAX Société Anonyme has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
ABIVAX Société Anonyme has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.19% of the float of ABIVAX Société Anonyme has been sold short.
Short Interest Ratio / Days to Cover
ABIVAX Société Anonyme has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ABIVAX Société Anonyme has recently decreased by 29.54%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
ABIVAX Société Anonyme does not currently pay a dividend.
Dividend Growth
ABIVAX Société Anonyme does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ABVX.

2.6

News and Social Media Coverage

News Sentiment
ABIVAX Société Anonyme has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for ABIVAX Société Anonyme this week, compared to 2 articles on an average week.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ABIVAX Société Anonyme insiders have not sold or bought any company stock.
Percentage Held by Institutions
47.91% of the stock of ABIVAX Société Anonyme is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ABIVAX Société Anonyme are expected to grow in the coming year, from ($2.98) to ($2.90) per share.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Global crypto currency reset (41 major banks signed up)

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

Here's everything you need to know.

About ABIVAX Société Anonyme Stock (NASDAQ:ABVX)

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

ABVX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ABVX Stock News Headlines

April 30, 2024 | americanbankingnews.com

ABIVAX Société Anonyme (NASDAQ:ABVX) Receives New Coverage from Analysts at Piper Sandler

April 30, 2024 | americanbankingnews.com

ABIVAX Société Anonyme (NASDAQ:ABVX) Receives New Coverage from Analysts at Guggenheim

May 5, 2024 | Colonial Metals (Ad)

The asset beating inflation by 4x

"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.

April 27, 2024 | americanbankingnews.com

ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Down 29.5% in April

April 10, 2024 | seekingalpha.com

ABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Call Transcript

April 10, 2024 | seekingalpha.com

ABVX ABIVAX Société Anonyme

April 2, 2024 | globenewswire.com

Abivax reports 2023 financial results and operational update

March 14, 2024 | morningstar.com

Abivax SA ADR ABVX

May 5, 2024 | Colonial Metals (Ad)

The asset beating inflation by 4x

February 23, 2024 | wsj.com

Abivax S.A. ADR

February 20, 2024 | finance.yahoo.com

ABIVAX Société Anonyme (ABVX.PA)

February 17, 2024 | morningstar.com

Abivax SA ABVX

February 13, 2024 | finance.yahoo.com

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)